Evan Seigerman
Stock Analyst at BMO Capital
(3.12)
# 1,259
Out of 5,048 analysts
146
Total ratings
53.12%
Success rate
9.72%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $426.00 | +24.41% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $101.57 | -40.93% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $84.69 | +41.69% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $141.96 | -18.99% | 15 | May 6, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $115 → $120 | $122.05 | -1.68% | 17 | Apr 17, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $151.44 | -8.21% | 27 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $46.02 | +32.55% | 11 | Nov 12, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $896.53 | +22.81% | 8 | Aug 9, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $32.76 | +22.10% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $9.31 | +329.88% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $642.25 | +22.69% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $5.17 | -51.64% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $296.30 | -17.99% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.22 | +129.89% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $24.66 | +143.31% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.58 | +1,798.73% | 3 | May 12, 2020 |
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $426.00
Upside: +24.41%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $101.57
Upside: -40.93%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $84.69
Upside: +41.69%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $141.96
Upside: -18.99%
Gilead Sciences
Apr 17, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $122.05
Upside: -1.68%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $151.44
Upside: -8.21%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $46.02
Upside: +32.55%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $896.53
Upside: +22.81%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $32.76
Upside: +22.10%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $9.31
Upside: +329.88%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $642.25
Upside: +22.69%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $5.17
Upside: -51.64%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $296.30
Upside: -17.99%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.22
Upside: +129.89%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $24.66
Upside: +143.31%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.58
Upside: +1,798.73%